EU & US At Odds Over Merck’s Keytruda
Decisions Show How Regulators Can Differ Over Same Data
Executive Summary
EU and US regulators have opposing views when it comes to Merck's applications for a new indication and new dosing schedule for the company's successful PD-1 inhibitor Keytruda.
You may also be interested in...
Keeping Track: US FDA Clears Esperion’s Nexletol, Baudax’ Anjeso, Agile’s Twirla
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
FDA Rejects Keytruda Dosing, Fast Tracks Tecentriq Lung Cancer Review
Keytruda is set to remain dominant despite knockback, though Tecentriq could claim prized NSCLC adjuvant approval first
BMS’s Opdivo On Track For Esophageal Cancer Indication
Opdivo showed a 23% fall in the risk of death and 2.5-month improvement in median overall survival compared to chemotherapy in Phase III esophageal cancer trial.